Lars Rönnstrand (Lars Ronnstrand)

Scopus Author ID Scopus Author ID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 13

Top Venues

Scientific reports

Blood cancer journal

Molecular cancer research : MCR

Oncogene

Lund University

Uppsala University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Lund University

Sweden

Professor of Molecular Medicine

Ludwig Institute for Cancer Research Uppsala Branch of Growth Regulation

Sweden

Associate Member

Ludwig Institute for Cancer Research Uppsala Branch of Growth Regulation

Sweden

Assistant Member

Ludwig Institute for Cancer Research Uppsala Branch of Growth Regulation

Sweden

Postdoctoral Fellow

Memorial Sloan-Kettering Cancer Center

United States

Postdoctoral Fellow

Education History

Uppsala University

Sweden

PHD :: Dept. of Medical and Physiological Chemistry

Lund University

Sweden

BSC

Publications

Hongxia Chen, Yunpeng Bai, Michihiro Kobayashi, Shiyu Xiao, Sergio Barajas, Wenjie Cai, Sisi Chen, Jinmin Miao, Frederick Nguele Meke, Chonghua Yao, Yuxia Yang, Katherine Strube, Odelia Satchivi, Jianmin Sun, Lars Rönnstrand, James M Croop, H Scott Boswell, Yuzhi Jia, Huiping Liu, Loretta S Li, Jessica K Altman, Elizabeth A Eklund, Madina Sukhanova, Peng Ji, Wei Tong, Hamid Band, Danny T Huang, Leonidas C Platanias, Zhong-Yin Zhang, Yan Liu
PRL2 phosphatase promotes oncogenic KIT signaling in leukemia cells through modulating CBL phosphorylation. Molecular cancer research : MCR (2023)
Julhash U Kazi, Lina Al Ashiri, Rituraj Purohit, Lars Rönnstrand
Understanding the Role of Activation Loop Mutants in Drug Efficacy for FLT3-ITD. Cancers 15 (22) (2023)
Sausan A Moharram, Kinjal Shah, Fatima Khanum, Lars Rönnstrand, Julhash U Kazi
The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia. Blood cancer journal 9 (2) (2019)
Julhash U Kazi, Lars Rönnstrand
FMS-like Tyrosine Kinase 3/FLT3: From Basic Science to Clinical Implications. Physiological reviews 99 (3) (2019)
Cathrine Nordgaard, Sophia Doll, Ana Laura de Souza Almeida Matos, Mikkel Høeberg, Julhash Uddin Kazi, Stine Friis, Jan Stenvang, Lars Rönnstrand, Matthias Mann, José Manuel Afonso Moreira
Metallopeptidase inhibitor 1 (TIMP-1) promotes receptor tyrosine kinase c-Kit signaling in colorectal cancer. Molecular oncology 13 (12) (2019)
Sausan A Moharram, Kinjal Shah, Fatima Khanum, Lars Rönnstrand, Julhash U Kazi
Correction: The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia. Blood cancer journal 9 (8) (2019)
Tianfeng Li, Yi Deng, Yu Shi, Ruijun Tian, Yonglong Chen, Lin Zou, Julhash U Kazi, Lars Rönnstrand, Bo Feng, Sun On Chan, Wai Yee Chan, Jianmin Sun, Hui Zhao
Bruton's tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma. Oncogene 37 (47) (2018)
Axel Hyrenius-Wittsten, Mattias Pilheden, Helena Sturesson, Jenny Hansson, Michael P Walsh, Guangchun Song, Julhash U Kazi, Jian Liu, Ramprasad Ramakrishan, Cristian Garcia-Ruiz, Stephanie Nance, Pankaj Gupta, Jinghui Zhang, Lars Rönnstrand, Anne Hultquist, James R Downing, Karin Lindkvist-Petersson, Kajsa Paulsson, Marcus Järås, Tanja A Gruber, Jing Ma, Anna K Hagström-Andersson
De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia. Nature communications 9 (1) (2018)
Alissa Marhäll, Florian Heidel, Thomas Fischer, Lars Rönnstrand
Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation. Annals of hematology 97 (5) (2018)
Jianmin Sun, Tine Thingholm, Peter Højrup, Lars Rönnstrand
XK-related protein 5 (XKR5) is a novel negative regulator of KIT/D816V-mediated transformation. Oncogenesis 7 (6) (2018)
Kaja Rupar, Sausan A Moharram, Julhash U Kazi, Lars Rönnstrand
SRC-like adaptor protein 2 (SLAP2) is a negative regulator of KIT-D816V-mediated oncogenic transformation. Scientific reports 8 (1) (2018)
Julhash U Kazi, Rohit A Chougule, Tianfeng Li, Xianwei Su, Sausan A Moharram, Kaja Rupar, Alissa Marhäll, Mohiuddin Gazi, Jianmin Sun, Hui Zhao, Lars Rönnstrand
Tyrosine 842 in the activation loop is required for full transformation by the oncogenic mutant FLT3-ITD. Cellular and molecular life sciences : CMLS 74 (14) (2017)
Alissa Marhäll, Julhash U Kazi, Lars Rönnstrand
The Src family kinase LCK cooperates with oncogenic FLT3/ITD in cellular transformation. Scientific reports 7 (1) (2017)

Lars Rönnstrand.css-eqlu8i{font-size:small;padding-left:4px;} (Lars Ronnstrand)

Publication Activity (10 Years)

Top Topics

Top Venues

Lars Rönnstrand (Lars Ronnstrand)